
- Sanofi‘s Business EPS for Q2 was €1.59, lower than the estimate of €1.67, but slightly up from the previous year’s €1.56.
- Q2 sales reached €9.99 billion, exceeding the anticipated €9.78 billion and reflecting a 6% year-over-year increase.
- Dupixent’s net product sales were €3.83 billion, slightly surpassing the forecast of €3.81 billion.
- Beyfortus achieved net sales of €72 million, significantly beating the estimate of €44.4 million.
- Aubagio’s net sales were €73 million, above the projected €57.8 million.
- Influenza vaccines generated sales of €141 million, outperforming the predicted €115 million.
- At constant exchange rates, overall sales grew by 10.1%.
- Dupixent sales rose by 21.1% at constant exchange rates.
- Beyfortus sales surged by 322.2% at constant exchange rates.
- Aubagio sales declined by 29% at constant exchange rates.
- The influenza vaccine sales increased by 26.1% at constant exchange rates.
- Biopharma net sales matched total sales at €9.99 billion, slightly above the €9.79 billion estimate, with a 10.1% increase at constant exchange rates.
- Business net income was €1.94 billion, a slight 0.6% decrease year-over-year and below the expected €2.02 billion.
- The business operating income fell by 2.4% year-over-year to €2.46 billion, under the forecast of €2.57 billion.
- The gross margin improved to 77.5%, up from last year’s 76%, and higher than the estimated 77%.
- Biopharma’s gross margin was 77%, compared to the previous year’s 75.8% and an expected 76.7%.
- R&D expenses increased by 15% year-over-year, reaching €1.91 billion, slightly higher than the estimate of €1.87 billion.
- Free cash flow stood at €1.43 billion.
- Sanofi expects full-year sales to increase by a high single-digit percentage at constant exchange rates.
- The company confirms a strong business EPS rebound for the full year, projecting a low double-digit percentage growth at constant exchange rates, including expenses from newly acquired businesses.
“`
A look at Sanofi Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Sanofi, a pharmaceutical company known for its prescription drugs and vaccines, has received a positive overall outlook based on Smartkarma Smart Scores. With a strong dividend score of 4 and high resilience score of 4, Sanofi demonstrates stability and shareholder returns. The company’s focus on manufacturing essential medicines in areas such as cardiovascular, metabolic disorders, and oncology contributes to its growth score of 3. However, with a lower momentum score of 2, Sanofi may face challenges in maintaining market traction in the near future.
In summary, Sanofi‘s Smartkarma Smart Scores paint a picture of a company with solid value, dividend payouts, and resilience in the face of uncertainties. Its diverse portfolio of pharmaceutical products caters to global customers, showcasing its commitment to innovation and healthcare. Investors may find Sanofi an attractive long-term investment option, leveraging on its established presence in the pharmaceutical industry and strong financial performance in key areas.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars